Denali Therapeutics price target lowered to $50 from $80 at Evercore ISI

Evercore ISI lowered the firm’s price target on Denali Therapeutics to $50 from $80 and keeps an Outperform rating on the shares, citing a "growing appreciation of how long it will take for trials of interest to read-out and support approval." The firm’s pushed out launch timeline expectations drive its lower price target.